Neoadjuvant chemotherapy with atezolizumab, bevacizumab, and FOLFOX for patients with unresectable colorectal liver metastases: A translational pilot study

被引：0
|
作者：
Kim, Sun Young
Kim, Wonkyung
Sung, Chang Ohk
Kim, Jihun
Hong, Yong Sang
Kim, Jeong Eun
Kim, Tae Won
机构：
[1] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[3] Univ Ulsan, Dept Pathol, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3573
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effect of Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases
    Zhu, Dexiang
    Zhong, Yunshi
    Wei, Ye
    Ye, Lechi
    Lin, Qi
    Ren, Li
    Ye, Qinghai
    Liu, Tianshu
    Xu, Jianmin
    Qin, Xinyu
    PLOS ONE, 2014, 9 (01):
  • [22] The Role of Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases
    Ayez, N.
    Grunhagen, D. J.
    De Jonge, J.
    Ijzermans, J. N.
    Eggermont, A. M.
    Verhoef, C.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S35 - S35
  • [23] EFFECT OF NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH RESECTABLE COLORECTAL LIVER METASTASES
    Zhu, D.
    Xu, J.
    Zhong, Y.
    Wei, Y.
    ANNALS OF ONCOLOGY, 2013, 24
  • [24] Effect of Neoadjuvant Chemotherapy in Patients with Colorectal Cancer Liver Metastases
    Sui, Kenta
    Okabayashi, Takehiro
    Iwata, Jun
    Morita, Sojiro
    Matsumoto, Takatsugu
    Inada, Ryo
    Iiyama, Tatsuo
    Shimada, Yasuhiro
    Kobayashi, Michiya
    SURGICAL TECHNOLOGY INTERNATIONAL-INTERNATIONAL DEVELOPMENTS IN SURGERY AND SURGICAL RESEARCH, 2019, 34
  • [25] Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma
    Duffy, Austin
    Shia, Jinru
    Huitzil-Melendez, Fidel David
    Fong, Yuman
    O'Reilly, Eileen M.
    CLINICAL COLORECTAL CANCER, 2008, 7 (02) : 140 - 143
  • [26] FOLFOX-based hepatic arterial infusion chemotherapy combined with regorafenib for unresectable colorectal liver metastases
    Song, Songlin
    Liu, Jiacheng
    Ren, Yanqiao
    Zheng, Chuansheng
    Liang, Bing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Combined systemic and regional chemotherapy in patients with unresectable colorectal liver metastases
    Uzzau, A
    Sorrentino, M
    Scanavacca, F
    Iop, A
    Cartei, G
    Soro, P
    Bresadola, F
    HAMBURG '97 - EUROPEAN I.H.P.B.A. CONGRESS, 1997, : 285 - 288
  • [28] CEA Change After Neoadjuvant Chemotherapy Including Bevacizumab and Clinical Outcome in Patients Undergoing Liver Resection for Colorectal Liver Metastases
    Stremitzer, Stefan
    Stift, Judith
    Graf, Alexandra
    Singh, Jagdeep
    Starlinger, Patrick
    Gruenberger, Birgit
    Tamandl, Dietmar
    Gruenberger, Thomas
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (04) : 1315 - 1323
  • [29] Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with microsatellite-stable colorectal liver metastases
    Stift, Judith
    Graf, Alexandra
    Neudert, Barbara
    Herac, Merima
    Woeran, Katharina
    Tamandl, Dietmar
    Laengle, Johannes
    Schwarz, Christoph
    Wrba, Friedrich
    Kaczirek, Klaus
    Stremitzer, Stefan
    HPB, 2022, 24 (01) : 40 - 46
  • [30] Influence of KRAS status of colorectal cancer liver metastases in patients receiving neoadjuvant chemotherapy including Bevacizumab prior liver resection
    Stremitzer, S.
    Maresch, J.
    Aschacher, T.
    Wolf, B.
    Wrba, F.
    Gruenberger, T.
    Gruenberger, B.
    ONKOLOGIE, 2011, 34 : 247 - 247
12345